MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
8.42
+0.17
+2.06%
After Hours: 8.42 0 0.00% 16:10 12/05 EST
OPEN
8.33
PREV CLOSE
8.25
HIGH
8.45
LOW
8.23
VOLUME
20.75K
TURNOVER
--
52 WEEK HIGH
21.94
52 WEEK LOW
4.850
MARKET CAP
34.06M
P/E (TTM)
0.1579
1D
5D
1M
3M
1Y
5Y
1D
FibroGen to Present at Oppenheimer Movers in Rare Disease Summit
Reuters · 3d ago
Weekly Report: what happened at FGEN last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at FGEN last week (1117-1121)?
Weekly Report · 11/24 09:17
CEO’s Bold Move: Major Investment in FibroGen Stock!
TipRanks · 11/18 02:10
Weekly Report: what happened at FGEN last week (1110-1114)?
Weekly Report · 11/17 09:17
FibroGen’s Earnings Call: Strategic Moves Amid Financial Caution
TipRanks · 11/12 00:15
Analysts Are Bullish on Top Healthcare Stocks: Akebia Therapeutics (AKBA), FibroGen (FGEN)
TipRanks · 11/11 11:50
FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
TipRanks · 11/11 09:15
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.